Idenix May Drop Delayed Hepatitis C Drug for New Versions

Idenix Pharmaceuticals Inc., a developer of hepatitis C drugs, may shelve experimental treatments currently on hold by U.S. regulators and focus on different versions, Chief Executive Officer Ron Renaud said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.